Med-Surge Takes Aim At Candela In Targeting Facial Acne, Sebaceous Glands
This article was originally published in The Gray Sheet
Executive Summary
Med-Surge is positioning itself to be a direct competitor to Candela in the laser acne treatment market with a planned facial indication for its "non-ablative" Aramis Er: Glass system
You may also be interested in...
Aesthetic Device Firms Eye Gains From Expanding Treatment Awareness
Makers of aesthetic surgery devices are counting on heightened public awareness of expanding treatment options in 2003, coupled with the improving economy, to help shape a robust market in the coming year
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.